Related Experiment Video
Updated: Jul 13, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Aromatase inhibitors--gene discovery.
William R Miller1, Alexey Larionov, Lorna Renshaw
1Breast Research Group, University of Edinburgh, Edinburgh, United Kingdom. wmiller@staffmail.edu.ac.uk
Summary
Microarray analysis of breast tumors reveals gene expression changes with letrozole treatment. Early gene expression profiles can predict treatment response, aiding in developing predictive indices for personalized therapy.
Area of Science:
- Oncology
- Genomics
- Pharmacogenomics
Background:
- Neoadjuvant treatment protocols involve administering therapy before primary tumor removal.
- Microarray analysis of tumor RNA allows global gene expression measurement.
- Sequential biopsies during neoadjuvant treatment can correlate gene expression with clinical response.
Purpose of the Study:
- To identify genes affected by estrogen deprivation induced by letrozole.
- To discover gene expression patterns that differentiate treatment-responsive from resistant tumors.
- To develop predictive indices for treatment response and resistance.
Main Methods:
- Microarray analysis of RNA from paired tumor biopsies before and after 14 days of letrozole treatment.
- Utilized three analytical approaches: frequency, magnitude, and Significance Analysis of Microarrays (SAM).
- Performed gene ontology and cluster analysis on identified differentially expressed genes.
Main Results:
- A total of 143 genes (91 down-regulated, 52 up-regulated) were identified. Down-regulated genes were linked to cell cycle progression (mitosis), while up-regulated genes were associated with organ development and extracellular matrix regulation.
- Microarray analysis identified 291 covariates (84 baseline, 72 at 14 days, 135 changes) highly predictive of clinical response.
- Responding tumors exhibited a distinct genetic profile compared to non-responding tumors.
Conclusions:
- Early changes in gene expression following letrozole treatment are indicative of treatment response.
- Gene expression profiling holds potential for developing predictive biomarkers for neoadjuvant therapy in breast cancer.
- Distinct molecular signatures differentiate responders from non-responders, paving the way for personalized treatment strategies.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...